Age is an independent adverse prognostic factor for overall survival in acute myeloid leukemia in Japan

Table 1 Characteristics of non-acute promyelocytic leukemia patients

		Number of patients
Parameter	Category	All patients (n = 197)		Age in year
				≤64 (n = 74)		65-74 (n = 50)		≥75 (n = 73)
Gender	Female	78	39.60%	30	40.50%	19	38.00%	29	39.70%
	Male	119	60.40%	44	59.50%	31	62.00%	44	60.30%
FAB classification	M0	9	4.60%	3	4.10%	0	0.00%	6	8.20%
	M1	24	12.20%	10	13.50%	4	8.00%	10	13.70%
	M2	100	50.80%	34	45.90%	27	54.00%	39	53.40%
	M4	24	12.20%	11	14.90%	7	14.00%	6	8.20%
	M5	10	5.10%	5	6.80%	3	6.00%	2	2.70%
	M6	13	6.60%	3	4.10%	4	8.00%	6	8.20%
	M7	4	2.00%	2	2.70%	1	2.00%	1	1.40%
Myelodysplasia	Yes	93	47.20%	32	43.20%	20	40.00%	41	56.20%	a
	No	100	50.80%	40	54.10%	29	58.00%	31	42.50%
Performance status	0-1	98	49.70%	45	60.80%	28	56.00%	25	34.20%
	2	46	23.40%	13	17.60%	8	16.00%	25	34.20%
	3-4	49	24.90%	14	18.90%	13	26.00%	22	30.10%
Karyotype risk category
NCCN	F	13	6.60%	9	12.20%	2	4.00%	2	2.70%	a
	I	122	61.90%	43	58.10%	27	54.00%	52	71.20%
	U	46	23.40%	16	21.60%	19	38.00%	11	15.10%
SWOG	F	10	5.10%	7	9.50%	2	4.00%	1	1.40%	a
	I	97	49.20%	35	47.30%	23	46.00%	39	53.40%
	U	59	29.90%	20	27.00%	21	42.00%	18	24.70%
	others	15	7.60%	6	8.10%	2	4.00%	7	9.60%
CALGB	F	13	6.60%	9	12.20%	3	6.00%	1	1.40%	a
	I	100	50.80%	33	44.60%	26	52.00%	41	56.20%
	U	45	22.80%	15	20.30%	16	32.00%	14	19.20%
	others	39	19.80%	17	23.10%	5	10.00%	17	23.20%
Antecedent	No	158	80.20%	60	81.10%	37	74.00%	61	83.60%
hematologic disease	Yes	36	18.30%	13	17.60%	11	22.00%	12	16.40%
Prior chemotherapy	No	174	88.30%	65	87.80%	41	82.00%	68	93.20%
	Yes	19	9.60%	7	9.50%	7	14.00%	5	6.80%
Laboratory findings
WBC (× 103/mL)	< 100	178	90.40%	65	87.80%	48	96.00%	65	89.00%
	≥ 100	16	8.10%	7	9.50%	1	2.00%	8	11.00%
Hemoglobin (g/dL)	< 8.0	93	47.20%	36	48.60%	23	46.00%	34	46.60%
	≥ 8.0	101	51.30%	36	48.60%	26	52.00%	39	53.40%
Platelet (× 104/mL)	< 5.0	85	43.10%	29	39.20%	23	46.00%	33	45.20%
	5.0-10.0	64	32.50%	25	33.80%	20	40.00%	19	26.00%
	≥ 10.0	45	22.80%	18	24.30%	6	12.00%	21	28.80%
% Blast in blood	< 20	89	45.20%	28	37.80%	29	58.00%	32	43.80%
	20-50	43	21.80%	17	23.00%	11	22.00%	15	20.50%
	> 50	59	29.90%	27	36.50%	8	16.00%	24	32.90%
% Blast in marrow	< 50	98	49.70%	33	44.60%	30	60.00%	35	47.90%
	≥ 50	84	42.60%	35	47.30%	18	36.00%	31	42.50%
LDH (IU/L)	< 250	58	29.40%	15	20.30%	24	48.00%	19	26.00%	a
	250-500	75	38.10%	27	36.50%	14	28.00%	34	46.60%
	> 500	59	29.90%	29	39.20%	11	22.00%	19	26.00%
Creatinine (mg/dL)	≤ 1.3	162	82.20%	66	89.20%	41	82.00%	55	75.30%
	> 1.3	29	14.70%	5	6.80%	8	16.00%	16	21.90%
Infection at	No	146	74.10%	52	70.20%	39	78.00%	55	75.30%	a
induction therapy	Yes	48	24.30%	20	27.00%	10	20.00%	18	24.60%
Intensity of	Intensive	102	51.70%	53	71.60%	23	46.00%	26	35.60%	a
induction therapy	Less-intensive	56	28.40%	13	17.50%	19	38.00%	24	32.80%
	BSC	39	19.70%	8	10.80%	8	16.00%	23	31.50%

^aP < 0.05 vs total. F: Favorable; I: Intermediate; U: Unfavorable; WBC: White blood cell; NCCN: National Comprehensive Cancer Network; SWOG: Southwest Oncology Group; CALGB: Cancer and Leukemia Group B; LDH: Lactase dehydrogenase.